Diamond Biotechnology Co (ROCO:6815) Other Current Receivables: NT$4.1 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6815 Diamond Biotechnology Co Ltd ROCO:6815
77 GF Score
Price NT$25.50
GF Value NT$48.15
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Diamond Biotechnology Co Other Current Receivables?

Diamond Biotechnology Co ROCO:6815 -4.49% 77 Other Current Receivables is NT$4.1 Mil as of Dec. 2025. GuruFocus rates ROCO:6815 with a GF Score™ of 77/100 and a GF Value™ of NT$48.15 (Possible Value Trap). The stock has 7 warning signs investors should review.

Diamond Biotechnology Co's Other Current Receivables for the quarter that ended in Dec. 2025 was NT$4.1 Mil.

Diamond Biotechnology Co's quarterly Other Current Receivables declined from Dec. 2024 (NT$22.76 Mil) to Jun. 2025 (NT$8.35 Mil) but then stayed the same from Jun. 2025 (NT$8.35 Mil) to Dec. 2025 (NT$4.10 Mil).

Diamond Biotechnology Co's annual Other Current Receivables increased from Dec. 2023 (NT$8.31 Mil) to Dec. 2024 (NT$22.76 Mil) but then declined from Dec. 2024 (NT$22.76 Mil) to Dec. 2025 (NT$4.10 Mil).

Diamond Biotechnology Co Other Current Receivables Related Terms

Diamond Biotechnology Co Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Diamond Biotechnology Co's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diamond Biotechnology Co Other Current Receivables Chart

Diamond Biotechnology Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only 4.70 2.00 8.31 22.76 4.10

Diamond Biotechnology Co Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.31 33.55 22.76 8.35 4.10
ROCO:6815
77GF Score
Diamond Biotechnology Co Ltd ROCO:6815
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diamond Biotechnology Co Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of NT$4.1 Mil mean?
Diamond Biotechnology Co (ROCO:6815) has a Other Current Receivables of NT$4.1 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Diamond Biotechnology Co and its competitors.
Is Diamond Biotechnology Co's Other Current Receivables too high?
Diamond Biotechnology Co's current Other Current Receivables is NT$4.1 Mil. Overall, Diamond Biotechnology Co has a GF Score™ of 77/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Diamond Biotechnology Co's Other Current Receivables compare to ABT and SYK?
Diamond Biotechnology Co's Other Current Receivables of NT$4.1 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Medical Devices & Instruments company?
A good Other Current Receivables depends on the Medical Devices & Instruments industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Diamond Biotechnology Co and its competitors. Diamond Biotechnology Co's current Other Current Receivables is NT$4.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamond Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Diamond Biotechnology Co (ROCO:6815) is currently considered Possible Value Trap. The stock's GF Value™ is NT$48.15, compared to a current price of NT$25.50 — trading 47% below its estimated fair value. The current Other Current Receivables is NT$4.1 Mil. Diamond Biotechnology Co's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Diamond Biotechnology Co (ROCO:6815), the current Other Current Receivables is NT$4.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diamond Biotechnology Co (ROCO:6815) Overvalued in 2026?

Based on GuruFocus' analysis, Diamond Biotechnology Co stock appears to be undervalued. The current stock price of NT$25.50 is trading 47% below its estimated GF Value™ of NT$48.15. GuruFocus considers Diamond Biotechnology Co to be Possible Value Trap.

Key valuation signals for ROCO:6815:

  • Other Current Receivables: NT$4.1 Mil
  • GF Value™: NT$48.15 vs. price of NT$25.50 (47% below fair value)
  • GF Score™: 77/100 with 7 warning signs

No single metric tells the full story. See the ROCO:6815 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diamond Biotechnology Co Business Description

Address No. 45, Section 2, Fuxing South Road, Da'an District, 11th Floor, Taipei, TWN
Diamond Biotechnology Co Ltd is engaged in the research and development of medical equipment, and medical consumables. It also manufactures and sells medical beauty-level skincare products.
77GF Score

Get the complete analysis for ROCO:6815

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$25.50
Price
NT$48.15
GF Value